

FOI 3040

30th April 2025**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

Question 1. How many patients were treated in the last 4 months (December 2024 to March 2025) by the dermatology department with each of the following products:

Response:

Current patients as of 10/04/2025

- Abrocitinib - 1
- Baricitinib - 1
- Dupilumab - 131
- Lebrikizumab - 4
- Tralokinumab - 1
- Upadacitinib – 37

Please be advised that Pharmacy do not hold individual patient data for any of the following drugs

- Acitretin
- Alitretinoin
- Azathioprine
- Ciclosporin
- Methotrexate
- Mycophenolate mofetil
- Pimecrolimus
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only
- Tacrolimus ointment
- Nemozumab

This information is not recorded centrally and therefore retrieving it would involve a manual search of individual patient records. As such, we cannot provide this information as the cost of locating and retrieving the information exceeds the “appropriate limit” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. In order to obtain this information from a number of individual patient records would exceed the £450 limit and is therefore cost prohibitive.

Under section 12 of the Freedom of Information Act 2000, Public Authorities are not obliged to comply with an information request where to do so would exceed the cost limit.

In addition, it would not be appropriate to search through individual patient records for the purposes for responding to a FOI request, there would be no patient expectation that medical records would be used in this way.

If you are able to refine your request, so that it is more likely to fall under the cost limit, we will consider it again. Please contact us for advice and assistance on refining your request if required.

Question 2. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

Response:

Please see below data for the 6 drugs responded to in question 1:

- Abrocitinib
 - Baricitinib
 - Dupilumab
 - Lebrikizumab
 - Tralokinumab
 - Upadacitinib
-
- 6 months to 5 - 0
 - Age 6-11 - 1
 - Age 12-17 - 9
 - Age 18 and above - 165

Email: Foi.Team@Southerntrust.hscni.net